PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Huynh, D.* ; Winter, P.* ; Märkl, F.* ; Endres, S. ; Kobold, S.

Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.

Semin. Immunopathol. 45, 215-227 (2022)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
The clinical use of cellular immunotherapies is gaining momentum and the number of approved indications is steadily increasing. One class of cellular therapies—chimeric antigen receptor (CAR)-modified T cells—has achieved impressive results in distinct blood cancer indications. These existing cellular therapies treating blood cancers face significant relapse rates, and their application beyond hematology has been underwhelming, especially in solid oncology. Major reasons for resistance source largely in the tumor microenvironment (TME). The TME in fact functionally suppresses, restricts, and excludes adoptive immune cells, which limits the efficacy of cellular immunotherapies from the onset. Many promising efforts are ongoing to adapt cellular immunotherapies to address these obstacles, with the aim of reshaping the tumor microenvironment to ameliorate function and to achieve superior efficacy against both hematological and solid malignancies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
11.759
2.459
7
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Car-t Cells ; Cellular Immunotherapy ; Cytokine ; Inflammation ; Stroma ; Tumor Microenvironment; Chimeric Antigen Receptor; Car-t-cells; Fibroblast Activation Protein; Dendritic Cells; Cancer-immunotherapy; Immune Surveillance; Antitumor Efficacy; Phase-i; Therapy; Recognition
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1863-2297
Zeitschrift Seminars in Immunopathology
Quellenangaben Band: 45, Heft: 2, Seiten: 215-227 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Berlin ; Heidelberg
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-522100-001
Förderungen
Marie-Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector Foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
Melanoma Research Alliance Grants
Else Kroner-Fresenius-Stiftung
German Cancer Aid
Ernst-Jung-Stiftung
LMU Munich's Institutional Strategy LMUexcellent
Bundesministerium fur Bildung und Forschung
European Research Council
German Research Foundation (DFG)
Fritz-Bender Foundation
Wilhelm-Sander-Stiftung
Deutsche Jose-Carreras Leukamie Stiftung
Projekt DEAL

Go-Bio initiative
DOI 10.1007/s00281-022-00962-4
WOS ID 000860366200001
WOS ID WOS:000860366200001
Scopus ID 85138911570
PubMed ID 36167831
Erfassungsdatum 2022-10-13
[➜Korrektur melden]